Horizon Space Acquisition II Corp. $60M IPO Priced

Biotechnology
Biotechnology
Initial Public Offering / IPO SPAC
Initial Public Offering / IPO SPAC

Show Chart?

Load external content from TradingView!

*You can change or withdraw your consent at any time in the footer under Cookies.

Horizon Space Acquisition II Corp. Prices $60 Million Initial Public Offering

NEW YORK, NY, USA November 14, 2024 Horizon Space Acquisition II Corp., a blank check company incorporated in the Cayman Islands, announced the pricing of its initial public offering (IPO) of 6,000,000 units at $10.00 per unit. This offering is valued at $60 million and is intended to facilitate a business combination with one or more businesses or entities.

Each unit comprises one ordinary share and one right, with each right entitling the holder to receive one-tenth (1/10) of an ordinary share upon the consummation of the company's initial business combination. The units are anticipated to begin trading on the Nasdaq Global Market (Nasdaq: HSPTU) on November 15, 2024. Once separate trading commences, the ordinary shares will trade under the symbol HSPT and the rights under HSPTR.

... Read on — Members only

About SL Science Holding Ltd

SL Bio is a biomedical company focused on developing innovative cellular and gene therapies for cancer treatment and regenerative medicine. Leveraging proprietary technologies and strategic partnerships, the company is advancing next-generation immunotherapies and exosome-based products for both medical and consumer applications. SL Bio’s approach combines scientific expertise with a commitment to improving patient outcomes and addressing unmet needs in healthcare. SL Bio also offers ISO-certified, dermatologically tested cow milk-derived exosome-based products and plant extract products for skin and hair care, with commercial distribution in Asia.

View Company Details

Initial Public Offering / IPO SPAC

SPAC IPO Calendar
SPAC IPO Events
Scroll to Top